scholarly journals Allogeneic Hematopoietic Stem Cell Transplantation from Sources other than Matched Related Donors in the Management of Elderly Acute Myeloid Leukemia Patients in First Complete Remission

2017 ◽  
Vol 6 (1) ◽  
pp. 45-51
Author(s):  
Yosuke Nagahata ◽  
Yuichiro Ono ◽  
Yotaro Ochi ◽  
Yusuke Koba ◽  
Yasuhiro Kazuma ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Complete Remission ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Myeloid Leukemia ◽  
Hematopoietic Stem ◽  
First Complete Remission ◽  
Acute Myeloid

Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4161-4161
Author(s):  
Yingjun Chang ◽  
Honghu Zhu ◽  
Lanping Xu ◽  
Hao Jiang ◽  
Daihong Liu ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Complete Remission ◽  
Stem Cell Transplantation ◽  
Myeloid Leukemia ◽  
Hematopoietic Stem ◽  
Poor Risk ◽  
First Complete Remission ◽  
Acute Myeloid

Abstract Abstract 4161 Purpose: The role of HLA-haploidentical related donors (HRD) hematopoietic stem-cell transplantation (HSCT) in first complete remission (CR1) for adults with intermediate and poor risk acute myeloid leukemia (AML) is still not clear. Patients and Methods: Totally 428 newly diagnosed AML patients between 15 and 60 years old were studied between Jan 2006 and May 2010. Among 240 patients with intermediate and poor risk cytogenetics, 191patients achieved CR1 and received chemotherapy alone or HSCT as post-remission treatment. Of these, 141 patients received chemotherapy alone (n=78) or HRD HSCT (n=63) were analyzed. Results: Up to last follow-up time of May 2011, 44 out of 141 patients died (36 died of relapse and 8 died of TRM) and 97 patients are still alive. 49 out of 141 patients experienced relapse and 84 patients are still in continuous CR1. The cumulative incidence of relapse (CIR) at 4 years was 37.4%±4.4%. Overall survival(OS) and disease-free survival(DFS) at 4 year was 63.8%±5.0% and 55.5%±4.9%, respectively. The CIR of HRD HSCT group was significantly lower than chemotherapy group(12.8%±6.1% vs.57.4%±5.6%, p<0.0001). HRD HSCT improved survival achieved by chemotherapy alone significantly (DFS at 4 years, 71.8%±6.9% v 42.6%±6.1%, p<0.0001;OS at 4 years,75.7% ±7.0% v 54.6%±6.1%, p=0.0014). Univariate and multivariate analysis showed post-remission treatment choice (HRD HSCT or chemotherapy) and high WBC at diagnosis were independent risk factor affecting relapse, DFS and OS. Conclusion: HRD HSCT in CR1 is superior to chemotherapy alone for adults with intermediate and poor risk AML patients. Disclosures: No relevant conflicts of interest to declare.

A Long-term Follow-up Analysis in Adult Acute Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation

2005 ◽  
Vol 91 (5) ◽  
pp. 388-393 ◽  
Author(s):  
Claudio Annaloro ◽  
Vittorio Ruggero Zilioli ◽  
Nicola Stefano Fracchiolla ◽  
Claudia Verier ◽  
Davide Soligo ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Complete Remission ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myeloid Leukemia ◽  
Hematopoietic Stem ◽  
Acute Myeloid

Aims and Background Over the last 17 years, 119 adult acute myeloid leukemia patients have undergone hematopoietic stem cell transplantation at our Center. Study Design Seventy patients in first complete remission received hematopoietic stem cell transplantation (28 allogeneic and 42 autologous HSCT) as late intensification after conventional chemotherapy; 38 patients received allogeneic hematopoietic stem cell transplantation in a more advanced phase. A reference group was built up by collecting 40 acute myeloid leukemia patients who received high-dose cytosine arabinoside as late intensification and whose complete remission lasted more than 10 months. Results Results of the study led to conclude that an earlier timing of allogeneic hematopoietic stem cell transplantation can be recommended in order to treat patients who would otherwise suffer an early relapse. Conclusions The outcome of autologous hematopoietic stem cell transplantation in patients not in first complete remission supports the possibility of achieving good quality second complete remissions and suggests that autografting may be a life-saving strategy in selected acute myeloid leukemia patients with advanced disease.

Sign in / Sign up

Export Citation Format

Share Document